| ObjectiveAccording to the recognitions of the Traditional Chinese Medicine on the lung cancer, we enacted the therapeutic principal which were dissipating phlegm, eliminating stagnation and benefiting vital energy. So we created the new prescription "Feijiyin", and observed the clinical therapeutic effecting and the safety of this traditional drug which was used as a adjunctive therapy on Tanyuzheng of the advanced stage of the non-small-cell lung carcinoma (NSCLC).All these had been done for the extended application on the clinical of this drug.Methods1. Selected 48 cases to make the prospective study. The cases were patients, who were treated from August 2009 to August 2010 at the Oncology service of the traditional Chinese medical (TCM) hospital of Hubei Province. And all cases, whose traditional medical types were Tanyuxing, were consistent with the diagnostic criteria of the non-small-cell lung cancer on the advanced stage. According to the treated order, they were randomly divided into two groups: the treatment group (n=23) and the control group (n=25). There were no significant deviation between the two groups on the age, the sex, the pathological type and the KPS Score and the total accumulated points of the traditional medical symptom before the therapy. They had comparability(P>0.05).2. The GP chemotherapy project was applied to the treatment group. At the same time, the traditional medical zheng differentiation-treatment(made the "Feijiyin" as the based prescription) was applied to the treatment group too.200ml-250ml Feijiyin were continually taken orally twice everyday for 2 cycles. 21days was a cycle. The control group was treated by using the chemotherapy project only.3.Over the treatment, we checked CT of the lung again, then recorded and evaluated the situation of lung lesion. Reliability examinations (the blood routine, the urine routine, the stool routine, the heart function, the liver function and the renal function), accumulated points of the traditional medical symptom on pro-treatment or post-treatment and KPS Score, and one-year survival rate were contrasted between the two groups to make a evaluation on the curative effect and the harmful and vice actions.4. The method of the statistics:SPSS17.0 was applied to process the data.Results1.The therapeutic effect in the near future:the stable rate of the treatment outstripped to the control group's rate, but it was not statistically significant between the two groups (P>0.05).2. The traditional medical symptom:the treatment group had more improvement on the clinical manifestation of disease'than the control group, and the diversity between the two groups had statistically significant (P<0.05).3. The quality of life:according to the KPS Score, on the quality of life, patients of the treatment group obviously had a more improvement than patients of the control group. The diversity had a statistical significance.4.The one-year survival rate:there had a significance difference between the two groups on the one-year survival rate of patients (P<0.05).Conclusion1.Made the traditional medical drug "Feijiyin" as an adjunctive therapy to the non-small cell lung cancer, it had no difference to be contrasted with the curative effect in the near future.2. The traditional medical drug "Feijiyin", to be used as an adjunctive therapy to the non-small-cell lung cancer, had a more progress than the simplified chemotherapy on the clinical symptom, the quality of life and the one-year survival rate. Those proved that the "Feijiyin" could reduce the toxity, increase efficiency and improve the total curative effect.3. The traditional medical drug "Feijiyin" had a better security on clinic. And no adverse reaction, related with the experiment'drugs, was observed during the period of the experiment. |
PDF Full Text Request